• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Where National Medicines Policies Have Taken Us With Patient Involvement and Health Technology Assessment in Africa.非洲国家药品政策在患者参与和卫生技术评估方面的进展
Front Med Technol. 2022 Feb 24;4:810456. doi: 10.3389/fmedt.2022.810456. eCollection 2022.
2
Patient advocacy group involvement in health technology assessments: an observational study.患者权益倡导组织参与卫生技术评估:一项观察性研究。
Res Involv Engagem. 2021 Nov 25;7(1):83. doi: 10.1186/s40900-021-00327-5.
3
The future of Cochrane Neonatal.考克兰新生儿协作网的未来。
Early Hum Dev. 2020 Nov;150:105191. doi: 10.1016/j.earlhumdev.2020.105191. Epub 2020 Sep 12.
4
A review of prospective pathways and impacts of COVID-19 on the accessibility, safety, quality, and affordability of essential medicines and vaccines for universal health coverage in Africa.关于2019年冠状病毒病对非洲全民健康覆盖所需基本药物和疫苗的可及性、安全性、质量及可负担性的潜在途径和影响的综述。
Global Health. 2021 Apr 8;17(1):42. doi: 10.1186/s12992-021-00666-8.
5
Rational use of medicines - Indian perspective!药品的合理使用——印度视角!
Int J Risk Saf Med. 2015;27 Suppl 1:S47-8. doi: 10.3233/JRS-150684.
6
A desktop review of evaluation of implementation of national medicines policies in SADC countries.对南部非洲发展共同体(SADC)国家国家药品政策实施情况评估的桌面审查。
Heliyon. 2023 Nov 13;9(11):e22218. doi: 10.1016/j.heliyon.2023.e22218. eCollection 2023 Nov.
7
Access to Cardiovascular Disease and Hypertension Medicines in Developing Countries: An Analysis of Essential Medicine Lists, Price, Availability, and Affordability.发展中国家心血管疾病和高血压药物的可及性:基本药物清单、价格、可获得性及可负担性分析
J Am Heart Assoc. 2020 May 5;9(9):e015302. doi: 10.1161/JAHA.119.015302. Epub 2020 Apr 25.
8
Value added medicines: what value repurposed medicines might bring to society?增值药物:重新利用的药物可能给社会带来什么价值?
J Mark Access Health Policy. 2016 Dec 23;5(1):1264717. doi: 10.1080/20016689.2017.1264717. eCollection 2017.
9
A new approach to gathering pharmaceutical market data to support policy implementation and access to medicines: as demonstrated by malaria medicines in Zambia.一种新方法来收集药品市场数据以支持政策实施和药品可及性:以赞比亚的抗疟药品为例。
Malar J. 2018 Nov 29;17(1):444. doi: 10.1186/s12936-018-2594-9.
10
Availability of Internationally Controlled Essential Medicines in the COVID-19 Pandemic.新型冠状病毒肺炎大流行期间国际管制基本药物的可及性
J Pain Symptom Manage. 2020 Aug;60(2):e48-e51. doi: 10.1016/j.jpainsymman.2020.04.153. Epub 2020 May 7.

引用本文的文献

1
Mitigating inequitable access to appropriate antibiotics in low- and middle-income countries.缓解低收入和中等收入国家在获取适当抗生素方面的不平等现象。
JAC Antimicrob Resist. 2025 Apr 24;7(2):dlaf061. doi: 10.1093/jacamr/dlaf061. eCollection 2025 Apr.
2
A desktop review of evaluation of implementation of national medicines policies in SADC countries.对南部非洲发展共同体(SADC)国家国家药品政策实施情况评估的桌面审查。
Heliyon. 2023 Nov 13;9(11):e22218. doi: 10.1016/j.heliyon.2023.e22218. eCollection 2023 Nov.
3
Civil society and medical product access in Africa: Lessons from COVID-19.非洲的民间社会与医疗产品获取:来自新冠疫情的经验教训
Front Med Technol. 2023 Feb 7;5:1091425. doi: 10.3389/fmedt.2023.1091425. eCollection 2023.

本文引用的文献

1
Can We Afford to Exclude Patients Throughout Health Technology Assessment?在整个卫生技术评估过程中,我们能承担得起将患者排除在外的后果吗?
Front Med Technol. 2022 Jan 25;3:796344. doi: 10.3389/fmedt.2021.796344. eCollection 2021.
2
Intellectual property waiver for covid-19 vaccines will advance global health equity.新冠疫苗的知识产权豁免将推动全球卫生公平。
BMJ. 2021 Aug 3;374:n1837. doi: 10.1136/bmj.n1837.
3
Patient involvement in regulation: an unvalued imperative.患者参与监管:一项未得到重视的必要之事。
Lancet. 2021 Jun 5;397(10290):2147-2148. doi: 10.1016/S0140-6736(21)00977-6.
4
Establishment of the African Medicines Agency: progress, challenges and regulatory readiness.非洲药品管理局的设立:进展、挑战与监管准备情况
J Pharm Policy Pract. 2021 Mar 8;14(1):29. doi: 10.1186/s40545-020-00281-9.
5
(Re)defining legitimacy in Canadian drug assessment policy? Comparing ideas over time.(重新)定义加拿大药物评估政策的合法性?随时间比较观念的变化。
Health Econ Policy Law. 2021 Oct;16(4):424-439. doi: 10.1017/S1744133121000013. Epub 2021 Feb 9.
6
Patients and public are important stakeholders in health technology assessment but the level of involvement is low - a call to action.患者和公众是卫生技术评估中的重要利益相关者,但他们的参与程度较低——行动呼吁。
Res Involv Engagem. 2021 Jan 5;7(1):1. doi: 10.1186/s40900-020-00248-9.
7
Ongoing strategies to improve the management of upper respiratory tract infections and reduce inappropriate antibiotic use particularly among lower and middle-income countries: findings and implications for the future.持续改善上呼吸道感染管理和减少不合理使用抗生素的策略,特别是在中低收入国家:发现和未来的启示。
Curr Med Res Opin. 2020 Feb;36(2):301-327. doi: 10.1080/03007995.2019.1700947. Epub 2019 Dec 30.
8
HISTORICAL DEVELOPMENT OF THE HTAsiaLINK NETWORK AND ITS KEY DETERMINANTS OF SUCCESS.HTAsiaLINK 网络的历史发展及其成功的关键因素。
Int J Technol Assess Health Care. 2018 Jan;34(3):260-266. doi: 10.1017/S0266462318000223. Epub 2018 Jun 18.
9
WHY PATIENTS SHOULD BE INVOLVED IN HEALTH TECHNOLOGY ASSESSMENT.为什么患者应该参与卫生技术评估。
Int J Technol Assess Health Care. 2017 Jan;33(1):1-4. doi: 10.1017/S0266462317000241. Epub 2017 May 22.
10
Universal health coverage, priority setting, and the human right to health.全民健康覆盖、优先事项设定与健康权
Lancet. 2017 Aug 12;390(10095):712-714. doi: 10.1016/S0140-6736(17)30931-5. Epub 2017 Apr 26.

非洲国家药品政策在患者参与和卫生技术评估方面的进展

Where National Medicines Policies Have Taken Us With Patient Involvement and Health Technology Assessment in Africa.

作者信息

Sehmi Kawaldip, Wale Janet L

机构信息

International Alliance of Patients' Organizations, London, United Kingdom.

HTAi Patient and Citizen Involvement Interest Group (PCIG), Brunswick, VIC, Australia.

出版信息

Front Med Technol. 2022 Feb 24;4:810456. doi: 10.3389/fmedt.2022.810456. eCollection 2022.

DOI:10.3389/fmedt.2022.810456
PMID:35281672
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8915114/
Abstract

The Covid-19 pandemic has highlighted global knowledge about, but lack of equitable access to, life-changing medicines, and other innovative medical products by populations in African low and middle income countries. The World Health Organization (WHO) and other international non-profit foundations and organizations are constantly striving to address inequity. In the 1970s, WHO initiated a regularly updated essential medicines list, together with the concept of national medicines policies (NMPs) to ensure access and availability, affordability, rational, and effective use of medicines which are considered essential in addressing predominant population health issues and disease burden. We studied the NMPs of Ghana, South Africa, Uganda and Zimbabwe to highlight some of the important issues that these countries experience in the safe and effective use of medical products. Thailand is an example of how health technology assessment (HTA) can provide a country with an internationally supported, clearly defined and transparent process to broaden access to medicines and services. These medical services can add considerable value in accordance with local values and priorities. Involvement of civil society adds democratic legitimacy to such processes. Community health workers and patient advocacy groups are important in raising awareness and knowledge of safety issues and the effective use of quality medicines. They can apply pressure for increased funding to improve access to healthcare. Medicines and services that contribute to supported self-care are of benefit in any setting. Joint efforts across African countries such as with the African Medicines Agency are important in addressing some of the major health issues.

摘要

新冠疫情凸显了非洲低收入和中等收入国家民众对改变生活的药品及其他创新医疗产品的全球认知,但同时也暴露出这些产品在获取上缺乏公平性的问题。世界卫生组织(WHO)以及其他国际非营利基金会和组织一直在努力解决这种不公平现象。20世纪70年代,WHO发起了一份定期更新的基本药物清单,并提出了国家药物政策(NMPs)的概念,以确保获取和供应、可负担性、合理且有效地使用那些被认为对解决主要的民众健康问题和疾病负担至关重要的药物。我们研究了加纳、南非、乌干达和津巴布韦的国家药物政策,以突出这些国家在安全有效使用医疗产品方面所面临的一些重要问题。泰国是一个例子,说明卫生技术评估(HTA)如何能够为一个国家提供一个得到国际支持、明确界定且透明的程序,以扩大药品和服务的获取范围。这些医疗服务能够根据当地价值观和优先事项增加可观的价值。民间社会的参与为这类程序增添了民主合法性。社区卫生工作者和患者倡导团体对于提高对安全问题以及优质药物有效使用的认识和知识非常重要。他们可以施加压力以增加资金投入,改善医疗保健的获取。有助于支持自我护理的药品和服务在任何环境下都有益处。非洲国家之间的共同努力,比如与非洲药品管理局的合作,对于解决一些主要的健康问题至关重要。